Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

1.

A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT.

Brown CC, Havener TM, Medina MW, Auman JT, Mangravite LM, Krauss RM, McLeod HL, Motsinger-Reif AA.

Pharmacogenet Genomics. 2012 Nov;22(11):796-802. doi: 10.1097/FPC.0b013e3283589c50.

PMID:
23047291
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.

Moen EL, Stark AL, Zhang W, Dolan ME, Godley LA.

Mol Cancer Ther. 2014 May;13(5):1334-44. doi: 10.1158/1535-7163.MCT-13-0924. Epub 2014 Feb 25.

PMID:
24568970
[PubMed - indexed for MEDLINE]
3.

The A/G allele of rs16906252 predicts for MGMT methylation and is selectively silenced in premalignant lesions from smokers and in lung adenocarcinomas.

Leng S, Bernauer AM, Hong C, Do KC, Yingling CM, Flores KG, Tessema M, Tellez CS, Willink RP, Burki EA, Picchi MA, Stidley CA, Prados MD, Costello JF, Gilliland FD, Crowell RE, Belinsky SA.

Clin Cancer Res. 2011 Apr 1;17(7):2014-23. doi: 10.1158/1078-0432.CCR-10-3026. Epub 2011 Feb 25.

PMID:
21355081
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.

Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK.

Pediatr Blood Cancer. 2007 Apr;48(4):403-7.

PMID:
16609952
[PubMed - indexed for MEDLINE]
5.

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide.

van Nifterik KA, van den Berg J, van der Meide WF, Ameziane N, Wedekind LE, Steenbergen RD, Leenstra S, Lafleur MV, Slotman BJ, Stalpers LJ, Sminia P.

Br J Cancer. 2010 Jun 29;103(1):29-35. doi: 10.1038/sj.bjc.6605712. Epub 2010 Jun 1.

PMID:
20517307
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.

Taspinar M, Ilgaz S, Ozdemir M, Ozkan T, Oztuna D, Canpinar H, Rey JA, Sunguro─člu A, Castresana JS, Ugur HC.

Tumour Biol. 2013 Jun;34(3):1935-47. doi: 10.1007/s13277-013-0738-7. Epub 2013 Mar 22.

PMID:
23519841
[PubMed - indexed for MEDLINE]
7.

STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression.

Kohsaka S, Wang L, Yachi K, Mahabir R, Narita T, Itoh T, Tanino M, Kimura T, Nishihara H, Tanaka S.

Mol Cancer Ther. 2012 Jun;11(6):1289-99. doi: 10.1158/1535-7163.MCT-11-0801. Epub 2012 Apr 24.

PMID:
22532597
[PubMed - indexed for MEDLINE]
Free Article
8.

Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.

Kitange GJ, Mladek AC, Carlson BL, Schroeder MA, Pokorny JL, Cen L, Decker PA, Wu W, Lomberk GA, Gupta SK, Urrutia RA, Sarkaria JN.

Clin Cancer Res. 2012 Aug 1;18(15):4070-9. doi: 10.1158/1078-0432.CCR-12-0560. Epub 2012 Jun 6.

PMID:
22675172
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients.

McDonald KL, Rapkins RW, Olivier J, Zhao L, Nozue K, Lu D, Tiwari S, Kuroiwa-Trzmielina J, Brewer J, Wheeler HR, Hitchins MP.

Eur J Cancer. 2013 Jan;49(2):360-8. doi: 10.1016/j.ejca.2012.08.012. Epub 2012 Sep 10.

PMID:
22975219
[PubMed - indexed for MEDLINE]
10.

Integrative genomic analysis of temozolomide resistance in diffuse large B-cell lymphoma.

Leshchenko VV, Kuo PY, Jiang Z, Thirukonda VK, Parekh S.

Clin Cancer Res. 2014 Jan 15;20(2):382-92. doi: 10.1158/1078-0432.CCR-13-0669. Epub 2013 Oct 31.

PMID:
24178621
[PubMed - indexed for MEDLINE]
Free Article
11.

Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression.

Bobola MS, Kolstoe DD, Blank A, Silber JR.

Mol Cancer Ther. 2010 May;9(5):1208-18. doi: 10.1158/1535-7163.MCT-10-0010.

PMID:
20457618
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.

Cen L, Carlson BL, Pokorny JL, Mladek AC, Grogan PT, Schroeder MA, Decker PA, Anderson SK, Giannini C, Wu W, Ballman KV, Kitange GJ, Sarkaria JN.

Neuro Oncol. 2013 Jun;15(6):735-46. doi: 10.1093/neuonc/not010. Epub 2013 Mar 10.

PMID:
23479134
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.

Ishii D, Natsume A, Wakabayashi T, Hatano H, Asano Y, Takeuchi H, Shimato S, Ito M, Fujii M, Yoshida J.

Neurol Med Chir (Tokyo). 2007 Aug;47(8):341-9; discussion 350.

PMID:
17721049
[PubMed - indexed for MEDLINE]
Free Article
14.

JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression.

Okada M, Sato A, Shibuya K, Watanabe E, Seino S, Suzuki S, Seino M, Narita Y, Shibui S, Kayama T, Kitanaka C.

Int J Oncol. 2014 Feb;44(2):591-9. doi: 10.3892/ijo.2013.2209. Epub 2013 Dec 5.

PMID:
24316756
[PubMed - indexed for MEDLINE]
15.

Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.

Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, Kelly J, McGown G, Thorncroft M, Carlson BL, Sarkaria JN, Margison GP, Aldape K, Hawkins C, Hegi M, Guha A.

J Clin Invest. 2012 Jan 3;122(1):253-66. doi: 10.1172/JCI59334. Epub 2011 Dec 12. Erratum in: J Clin Invest. 2012 Feb 1;122(2):782.

PMID:
22156195
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.

Sato A, Sunayama J, Matsuda K, Seino S, Suzuki K, Watanabe E, Tachibana K, Tomiyama A, Kayama T, Kitanaka C.

Stem Cells. 2011 Dec;29(12):1942-51. doi: 10.1002/stem.753.

PMID:
21957016
[PubMed - indexed for MEDLINE]
Free Article
17.

Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status.

Makino K, Nakamura H, Hide T, Kuratsu J.

J Neurooncol. 2012 Jan;106(1):155-60. doi: 10.1007/s11060-011-0652-z. Epub 2011 Jul 1.

PMID:
21720808
[PubMed - indexed for MEDLINE]
18.

Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.

Happold C, Roth P, Wick W, Schmidt N, Florea AM, Silginer M, Reifenberger G, Weller M.

J Neurochem. 2012 Jul;122(2):444-55. doi: 10.1111/j.1471-4159.2012.07781.x. Epub 2012 May 28.

PMID:
22564186
[PubMed - indexed for MEDLINE]
19.

MGMT gene promoter methylation in pediatric glioblastomas.

Srivastava A, Jain A, Jha P, Suri V, Sharma MC, Mallick S, Puri T, Gupta DK, Gupta A, Sarkar C.

Childs Nerv Syst. 2010 Nov;26(11):1613-8. doi: 10.1007/s00381-010-1214-y. Epub 2010 Jun 29.

PMID:
20585787
[PubMed - indexed for MEDLINE]
20.

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome.

Hassel JC, Sucker A, Edler L, Kurzen H, Moll I, Stresemann C, Spieth K, Mauch C, Rass K, Dummer R, Schadendorf D.

Br J Cancer. 2010 Sep 7;103(6):820-6. doi: 10.1038/sj.bjc.6605796. Epub 2010 Aug 24.

PMID:
20736948
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk